Spotlight Growth
No Result
View All Result
Monday, March 20, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Evoke Pharma (NASDAQ: EVOK) Receives FDA Grant of New Drug Product Exclusivity for GIMOTI

by admin
April 26, 2022
in Bio/Med/Pharma
0
Evoke Pharma NASDAQ EVOK GIMOTI FDA Exclusivity Spotlight Growth

Evoke Pharma NASDAQ EVOK GIMOTI FDA Exclusivity Spotlight Growth

Evoke Pharma, Inc. (NASDAQ: EVOK) is engaged as a specialty pharmaceutical company, which is focused on the research and development of drugs to treat GI disorders and diseases. Shares of the specialty pharma company are skyrocketing 162% through early trading on Tuesday, April 26, 2022. Over the past three months, Evoke Pharma has seen average daily volume of 104,280 shares. However, volume of 131.1 million shares or dollar volume of around $135.03 million, has already exchanged hands through early trading.

Shares of Evoke Pharma are soaring after the company announced that its GIMOTI nasal spray has been granted new drug product exclusivity by the U.S. Food and Drug Administration (FDA). The market exclusivity grant now gives Evoke Pharma exclusive marketing rights for three years from the original date of approval. This gives the company protection under the Hatch-Waxman Act to shield GIMOTI from genetic drug competitors.

The specialty pharmaceutical company also holds a strong patent portfolio, which further protects GIMOTI from outside competition. Evoke Pharma currently has two Orange book-lsited patents entitled “Nasal Formulations of Metaclopramide,” U.S. Patent No. 11,020,361 and U.S. Patent No. 8,334,281, which expire in 2029 and 2030, respectively. Outside the U.S., the company has been granted gender-specific patents in the European Union, Japan and Mexico. Additional patents are pending.

Matt D’Onofrio, Evoke Pharma Chief Business Officer: “Receiving marketing exclusivity rights from the FDA for GIMOTI further establishes our proprietary concept of delivering an effective medication through the nasal pathway for the treatment of symptoms associated with diabetic gastroparesis. We are excited to continue our mission of getting GIMOTI to patients who are in need of a non-oral treatment for gastroparesis and capitalize on this large and growing market opportunity in the U.S.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: biopharmaceuticalsbiotechcommon stockdow jones todayemerging growthEVOKEVOK stockEvoke PharmaFDAFDA newsGIMOTIinvestinginvesting newsinvestmentmedicalmicrocap stocksNASDAQnewspharmaceuticalspublic companyRobinhoodrobinhood stockssalessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatmentwebull wallstreetbets
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
PureCycle Technologies NASDAQ PCT PureFive Distribution Agreement Formerra Spotlight Growth

PureCycle Technologies (NASDAQ: PCT) Enters Into Strategic Distribution Partnership With Formerra For its PureFive UPR Polypropylene Resin Product

March 16, 2023
Why Investors Are Worried About Credit Suisse NYSE CS Spotlight Growth

Why Are Investors Worried About Credit Suisse (NYSE: CS)?

March 15, 2023
Zero Days Till Expiration 0 DTE Options Trading Spotlight Growth

Zero Days Till Expiration (0 DTE) Options Trading: A High-Risk Strategy for Experienced Investors

March 15, 2023
ThermoGenesis NASDAQ THMO cGMP Facility Sacramento CA Spotlight Growth

ThermoGenesis (NASDAQ: THMO) Prepares Launch of ReadyStart cGMP Suites for Cell & Gene Therapy Companies

March 15, 2023

Recent News

PureCycle Technologies NASDAQ PCT PureFive Distribution Agreement Formerra Spotlight Growth

PureCycle Technologies (NASDAQ: PCT) Enters Into Strategic Distribution Partnership With Formerra For its PureFive UPR Polypropylene Resin Product

March 16, 2023
Why Investors Are Worried About Credit Suisse NYSE CS Spotlight Growth

Why Are Investors Worried About Credit Suisse (NYSE: CS)?

March 15, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested